Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

[Business Wire] – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Zydelig® 150 mg tablets for the treatment of three B-cell blood cancers. Read more on this. . . . → Read More: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma Similar Articles: Stock Update (NYSE:LLY): U.S. FDA approves Eli Lilly drug for stomach cancer Company Update: Biogen Idec Inc (NASDAQ:BIIB) – U.S. FDA approves Biogen’s hemophilia B drug Alprolix Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J, Pharmacyclics drug gets U.S. approval for leukemia